Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel leads for the Sanofi programs.
Sanofi has an exclusive option to license any compounds generated in the course of the collaboration. The financial terms of the agreement were not disclosed.
X-Chem CEO Rick Wagner said: "X-Chem has specifically built its library and discovery platform to address the challenges a broad range of targets and enable the discovery of multiple chemical series directly out of our primary screens.
"We are delighted to partner with Sanofi to identify lead molecules to difficult, high value therapeutic targets"
X-Chem senior VP of corporate development Ed Koval said: "This alliance, together with our recently announced collaboration and license agreements, further validates the high-value of our platform as well as X-Chem’s flexibility in finding win-win partnership frameworks for each of our collaborators."